Gliomas are the most lethal primary brain tumors in adults. These highly invasive tumors
have poor 5-year survival for patients. Gliomas are principally characterized by rapid …

Glioblastoma (GBM) is the most malignant primary brain tumor without effective therapies.
Since bevacizumab was FDA approved for targeting vascular endothelial growth factor …

Epigenetic lesions that disrupt regulatory elements represent potential cancer drivers.
However, we lack experimental models for validating their tumorigenic impact. Here, we …

Isocitrate dehydrogenase (IDH) mutants define a class of gliomas that are initially slow-
growing but inevitably progress to fatal disease. To characterize their malignant cell …

Background Glioblastoma multiforme (GBM), a lethal brain tumor, remains the most daunting
challenge in cancer therapy. Overexpression and constitutive activation of PDGFs and …

Platelet-derived growth subunit A (PDGFA) plays critical roles in development of
glioblastoma (GBM) with substantial evidence from TCGA database analyses and in vivo …

Glioblastoma multiforme is a highly malignant brain tumor with significant intra-and
intertumoral heterogeneity known for its aggressive nature and poor prognosis. The complex …

Malignant gliomas are known to be one of the most difficult diseases to diagnose and treat
because of the infiltrative growth pattern, rapid progression, and poor prognosis. Many …

The development and progression of a tumor depends on the close interaction of malignant
cells and the supportive and suppressive tumor microenvironment. Paracrine signaling …

Proteasome inhibitors bortezomib and carfilzomib are approved for the treatment of multiple
myeloma and mantle cell lymphoma and have demonstrated clinical efficacy for the …